- Home
- MARPS vs INTS Comparison
MARPS vs INTS Comparison
Compare MARPS & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MARPS
- INTS
- Stock Information
- Founded
- MARPS 1956
- INTS 2012
- Country
- MARPS United States
- INTS United States
- Employees
- MARPS N/A
- INTS N/A
- Industry
- MARPS Oil & Gas Production
- INTS Biotechnology: Pharmaceutical Preparations
- Sector
- MARPS Energy
- INTS Health Care
- Exchange
- MARPS Nasdaq
- INTS Nasdaq
- Market Cap
- MARPS 8.6M
- INTS 8.4M
- IPO Year
- MARPS N/A
- INTS 2023
- Fundamental
- Price
- MARPS $4.29
- INTS $0.29
- Analyst Decision
- MARPS
- INTS Strong Buy
- Analyst Count
- MARPS 0
- INTS 3
- Target Price
- MARPS N/A
- INTS $5.50
- AVG Volume (30 Days)
- MARPS 14.3K
- INTS 6.0M
- Earning Date
- MARPS 01-01-0001
- INTS 08-07-2025
- Dividend Yield
- MARPS 8.47%
- INTS N/A
- EPS Growth
- MARPS N/A
- INTS N/A
- EPS
- MARPS 0.36
- INTS N/A
- Revenue
- MARPS $1,036,019.00
- INTS N/A
- Revenue This Year
- MARPS N/A
- INTS N/A
- Revenue Next Year
- MARPS N/A
- INTS N/A
- P/E Ratio
- MARPS $11.78
- INTS N/A
- Revenue Growth
- MARPS N/A
- INTS N/A
- 52 Week Low
- MARPS $3.34
- INTS $0.19
- 52 Week High
- MARPS $7.90
- INTS $4.40
- Technical
- Relative Strength Index (RSI)
- MARPS 42.32
- INTS 47.56
- Support Level
- MARPS $4.37
- INTS $0.25
- Resistance Level
- MARPS $4.57
- INTS $0.32
- Average True Range (ATR)
- MARPS 0.26
- INTS 0.04
- MACD
- MARPS -0.04
- INTS 0.01
- Stochastic Oscillator
- MARPS 6.27
- INTS 62.69
About MARPS Marine Petroleum Trust Units of Beneficial Interest
Marine Petroleum Trust is a U.S based royalty trust. It provides administration and liquidation of rights to payments from oil and natural gas leases in the Gulf of Mexico. The Trust's subsidiary holds title to interests in properties which are situated offshore of Louisiana. The revenues of the trust are derived from the oil and natural gas production activities of third parties.
About INTS Intensity Therapeutics Inc. Common stock
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.